ArticleCardiovascular diabetology2026
Modulation of PKCα/ETS1 by klotho restores CYB5R4-dependent mitochondrial function in proximal tubular epithelial cells to attenuate the progression of diabetic kidney disease.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SPARC Drives Podocyte Mitochondrial Damage and Ferroptosis in Diabetic Kidney Disease Following Klotho Deficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveDiabetic kidney disease (DKD) progression involves early proximal tubular injury, which precedes podocyte injury. The protective role of the protein Klotho in DKD is well-documented, but its impact on early tubular injury and mitochondrial dysfunction in proximal tubule epithelial cells (PTECs) remains underexplored. This study aimed to determine whether Klotho alleviates DKD by targeting mitochondrial dysfunction in PTECs and to uncover the molecular mechanisms involved.
methodsThe role of Klotho was investigated using human kidney biopsies from patients at different DKD stages and a diabetic mouse model (induced by high-fat diet and streptozotocin). In vivo and in vitro techniques, including immunofluorescence, Western blot, transmission electron microscopy, and single-cell RNA sequencing, were used to assess tubular injury, mitochondrial integrity, and key protein interactions. The function of a newly identified protein, CYB5R4, was validated using knockdown and overexpression approaches in mouse models and human kidney (HK-2) cells.
resultsOur results reveal a novel molecular pathway where Klotho alleviates early tubular injury in DKD by targeting the mitochondrial protein CYB5R4. We demonstrate that CYB5R4 is critically downregulated in DKD and that its restoration is both necessary and sufficient for Klotho's protective effect on mitochondrial function in PTECs. This regulation follows a defined signaling cascade where Klotho suppresses PKCα, which in turn inhibits the transcription factor ETS1. This inhibition of ETS1 leads to the de-repression of the CYB5R4 promoter, ultimately reducing tubular apoptosis and injury. This CYB5R4-dependent mechanism positions CYB5R4 as a key therapeutic target.
conclusionOur findings uncover a novel Klotho/PKCα/ETS1/CYB5R4 signaling axis in PTECs that restores mitochondrial function and mitigates DKD progression, offering a promising therapeutic target for managing DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.